Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Differential effects of allosteric M(1) muscarinic acetylcholine receptor agonists on receptor activation, arrestin 3 recruitment, and receptor downregulation.

Davis AA, Heilman CJ, Brady AE, Miller NR, Fuerstenau-Sharp M, Hanson BJ, Lindsley CW, Conn PJ, Lah JJ, Levey AI.

ACS Chem Neurosci. 2010 Aug 18;1(8):542-551.

2.

Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.

Digby GJ, Shirey JK, Conn PJ.

Mol Biosyst. 2010 Aug;6(8):1345-54. doi: 10.1039/c002938f. Epub 2010 Jun 25. Review. Erratum in: Mol Biosyst. 2011 Dec;7(12):3376.

3.

Regulation of muscarinic acetylcholine receptor signaling.

van Koppen CJ, Kaiser B.

Pharmacol Ther. 2003 May;98(2):197-220. Review.

PMID:
12725869
4.

Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.

Conn PJ, Jones CK, Lindsley CW.

Trends Pharmacol Sci. 2009 Mar;30(3):148-55. doi: 10.1016/j.tips.2008.12.002. Epub 2009 Feb 7. Review.

5.

Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Jones CK, Byun N, Bubser M.

Neuropsychopharmacology. 2012 Jan;37(1):16-42. doi: 10.1038/npp.2011.199. Epub 2011 Sep 28. Review.

6.

Muscarinic receptor pharmacology and circuitry for the modulation of cognition.

Bubser M, Byun N, Wood MR, Jones CK.

Handb Exp Pharmacol. 2012;(208):121-66. doi: 10.1007/978-3-642-23274-9_7. Review.

PMID:
22222698
7.

Novel M(1) allosteric ligands: a patent review.

Kuduk SD, Beshore DC.

Expert Opin Ther Pat. 2012 Dec;22(12):1385-98. doi: 10.1517/13543776.2012.731395. Epub 2012 Oct 23. Review.

PMID:
23092292
8.

Cellular signaling mechanisms for muscarinic acetylcholine receptors.

Lanzafame AA, Christopoulos A, Mitchelson F.

Receptors Channels. 2003;9(4):241-60. Review.

PMID:
12893537
9.

Development of allosteric modulators of GPCRs for treatment of CNS disorders.

Nickols HH, Conn PJ.

Neurobiol Dis. 2014 Jan;61:55-71. doi: 10.1016/j.nbd.2013.09.013. Epub 2013 Sep 27. Review.

10.

Multiple mechanisms involving protein phosphorylation are linked to desensitization of muscarinic receptors.

Hosey MM, Benovic JL, DebBurman SK, Richardson RM.

Life Sci. 1995;56(11-12):951-5. Review.

PMID:
10188798
11.

Regulation of signal transduction at M2 muscarinic receptor.

Krejcí A, Michal P, Jakubík J, Rícný J, Dolezal V.

Physiol Res. 2004;53 Suppl 1:S131-40. Review.

12.

Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.

Davie BJ, Christopoulos A, Scammells PJ.

ACS Chem Neurosci. 2013 Jul 17;4(7):1026-48. doi: 10.1021/cn400086m. Epub 2013 May 23. Review.

13.

The antipsychotic potential of muscarinic allosteric modulation.

Bridges TM, LeBois EP, Hopkins CR, Wood MR, Jones CK, Conn PJ, Lindsley CW.

Drug News Perspect. 2010 May;23(4):229-40. doi: 10.1358/dnp.2010.23.4.1416977. Review.

14.

Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors.

Mohr K, Schmitz J, Schrage R, Tränkle C, Holzgrabe U.

Angew Chem Int Ed Engl. 2013 Jan 7;52(2):508-16. doi: 10.1002/anie.201205315. Epub 2012 Dec 6. Review.

PMID:
23225228
15.

The pharmacology of McN-A-343.

Mitchelson FJ.

Pharmacol Ther. 2012 Aug;135(2):216-45. doi: 10.1016/j.pharmthera.2012.05.008. Epub 2012 May 27. Review.

PMID:
22643681

Supplemental Content

Support Center